Cerebrolysin for acute ischaemic stroke
Review of earlier studies · 2023
- What was studied
- Cochrane review: 7 RCTs, including one Cortexin trial with 272 participants
- Main finding
- The pooled mortality analysis of Cerebrolysin or Cortexin found probably little or no difference (RR 0.96, 95% CI 0.65–1.41; 6 trials, 1,689 participants).
Reported findings and study design
2023 Cochrane review: seven randomized trials, 1,773 participants; includes a 272-person Cortexin trial. Mortality analysis: six trials, 1,689 participants.
Population or model Cochrane review: 7 RCTs, including one Cortexin trial with 272 participants
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| All-cause mortality | RR 0.96; 95% CI 0.65–1.41 | Cerebrolysin/Cortexin pooled; moderate-certainty evidence |
| Non-death attrition | RR 0.72; 95% CI 0.38–1.39 | Six trials, 1,689; very low certainty |
| Any serious adverse event | RR 1.16; 95% CI 0.81–1.66 | Cerebrolysin: three trials, 1,335 |
| Fatal serious adverse event | RR 0.90; 95% CI 0.59–1.38 | Cerebrolysin: three trials, 1,335 |
| Nonfatal serious adverse event | RR 2.39; 95% CI 1.10–5.23 | Cerebrolysin: three trials, 1,335 |
| Nonfatal SAE: 30 mL/day for ten days subgroup | RR 2.87; 95% CI 1.24–6.69 | Two trials, 1,189; cumulative dose 300 mL |
| Any adverse event | RR 1.03; 95% CI 0.92–1.14 | Four trials, 1,607 |
Mortality mixes two preparations; the serious-event estimates concern Cerebrolysin. A risk ratio whose interval crosses 1 is not a proven reduction or increase. Underlying trials overlap other pages.
Source for these results ↗ · Reviewed 2026-10-29
Study limitations and source details
Study limitations
- The pooled estimate is not Cortexin-only.
- The potential increase in nonfatal serious adverse events concerned Cerebrolysin and should not automatically be assigned to Cortexin.
Source details
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Sources checked
Citation
Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. Cerebrolysin for acute ischaemic stroke Cochrane Database Syst Rev 10:CD007026. PMID 37818733
Study source ↗ · DOI 10.1002/14651858.cd007026.pub7 · Bibliography entry · Link to this summary
Related compounds
Cortexin
A polypeptide extract of animal cerebral cortex. Its active material is a mixture of low-molecular-weight peptides studied in neurological rehabilitation, stroke and pediatric neurology.
Cerebrolysin
An injectable hydrolysate of porcine brain tissue containing small peptides and free amino acids. Clinical studies have examined recovery after stroke and cognition in Alzheimer’s disease.